Clinical research indicates that treatment with mineralocorticoid receptor antagonists (MRAs) can suppress the development of cardiac and kidney injury in patients with diabetes and hypertension but is limited by their ability to induce hyperkalaemia. The gene discussed is NR3C2; the disease is Hypertension.